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Summary
This prospective study is designed to identify novel ima-
ging (utilizing cardiovascular magnetic resonance and
advance echocardiography) and biochemical markers to
detect early, sub-clinical cardiotoxicity following
chemotherapy.
Background
Cardiac toxicity is an important long term side effect of
anthracyline chemotherapy. We hypothesized that novel
cardiovascular magnetic resonance (CMR) and echocar-
diographic markers of myocardial function, oedema, and
necrosis can detect early, subclinical cardiac toxicity in
patients receiving anthracycline therapy for breast
cancer.
Methods
29 chemonaive patients with breast cancer (early stage
and metastatic), underwent serial cardiovascular mag-
netic resonance imaging (for LV volumes/ejection frac-
tion, myocardial oedema and necrosis), advanced
echocardiography (for LV strain in addition to standard
measurements of LV diastolic function), pro brain
natriuretic peptide (pro-BNP) and high-sensitivity Tro-
ponin T (hs-TnT, Roche assay) measurements. All tests
were conducted at baseline, 1 month, and 3 months fol-
lowing commencement of anthracyclines. 6 normal
volunteers (3 male, 3 female) underwent the same CMR
protocol. For oedema imaging, a triple inversion
recovery fast-spin echo sequence (short-TI inversion
recovery) was used in 3 short-axis views of the left ven-
tricle. For assessment of myocardial oedema, the ratio of
mean signal intensity (SI) of the myocardium was com-
pared to that of skeletal muscle.
Results
In the study patients, the mean CMR LV end-systolic
volume index (LVESVI) increased from baseline of 17.8
± 6.2 to 20.3 ± 5.9 mL/m2 (p<0.001) at 1 month and
remained significantly elevated at 3 months (22.7 ± 5.6
mL/m2;p<0.001). Similarly, the end-diastolic volume
index (LVEDVI) increased from 62.9 ± 11.6 mL/m2 at 1
month to 66.4 ± 11.8(p<0.000) at 3 months . Echocar-
diographic measurement of global longitudinal strain
( G L S )s h o w e dn os i g n i f i c a n tc h a n g ea t1m o n t h ,h o w -
ever decreased in absolute magnitude from -21.4 ± 3%
baseline to -19.5 ± 1% (p ≤ 0.001) at 3 months. Left ven-
tricular diastolic function did not change significantly in
study patients, either 1 or 3 month post chemotherapy.
BNP did not correlate significantly with observed
changes in LVEDV, LVESV and GLS. Hs-TnT did not
change at 1 month but increased from 3.8 ± 1.6 to 10.7
±9 . 8a t3m o n t h s( p≤ 0.003). Although there was no
difference between baseline values of T2 ratio between
normal volunteers and study patients, 15/26 (58%) of
patients had an abnormal T2 signal (SI increase to > 1.9
as specified by Lake Louis criteria) in one or more short
axis slices post chemotherapy. There was no new late
gadolinium hyperenhancement to suggest focal myocar-
dial necrosis/fibrosis in any patient following therapy. 1Cardiology, Flinders Medical Centre, Adelaide, SA, Australia
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Our data suggest that there are subtle functional
changes in the LV myocardium early post anthracycline
chemotherapy that can be detected by both CMR and
advanced echocardiographic techniques. This is likely
mediated by myocardial inflammation (without necro-
sis). These findings may be a basis for development of
early predictors of cardiac damage and earlier interven-
tion/preventative strategies.
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